No CrossRef data available.
Article contents
PET-imaging of Cerebral Glucose Metabolism and of Cerebral Beta-amyloid-deposition and Its Value for the Understanding, Early Detection and Differential Diagnosis of Alzheimer's Disease
Published online by Cambridge University Press: 15 April 2020
Abstract
Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Alzheimer’s disease is now seen as a process that starts decades before cognitive impairment occurs and becomes severe enough to cause dementia.
It has been acknowledged, that biomarkers of this process (e.g.: CSF, structural MRI,FDG-PET (positron emission tomography), Amyloid-PET) increase diagnostic certainty and facilitate early diagnosis under the ultimate goal of early intervention.
This presentation will focus on PET-imaging of cerebral glucose metabolism by18-[F]-FDG-PET and cerebral beta-amyloid-deposition by the amyloid-binding PET Tracers (11-[C]-PiB, 18-[F]-Florbetapir, 18-[F]-Flutemetamol) and its value for the understanding, early detection and differential diagnosis of Alzheimer’sdisease.
It will highlight clinical situations in which these diagnostics are considered useful and potential caveats.
Finally it will provide a perspective how dementia diagnostics may evolve to in vivo assessment of pathology that predicts clinical phenotype and ideally therapeutic intervention.
- Type
- Article: 0025
- Information
- European Psychiatry , Volume 30 , Issue S1: Abstracts of the 23rd European Congress of Psychiatry , March 2015 , pp. 1
- Copyright
- Copyright © European Psychiatric Association 2015
You have
Access
Comments
No Comments have been published for this article.